SM-88 as Maintenance Therapy for Advanced Ewing's Sarcoma Patients and as Salvage Therapy for Sarcoma Patients
Status:
Recruiting
Trial end date:
2023-10-31
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate the efficacy of SM-88, a combination metabolic cancer
treatment, in two study cohorts:
- Clinically advanced Ewing's Sarcoma patients who have not progressed at the conclusion
of systemic treatment
- Clinically advanced sarcoma patients in the salvage treatment setting
Up to 24 efficacy evaluable patients (up to 12 per cohort) will be enrolled. Study patients
will receive oral SM-88, with scheduled safety and efficacy evaluations.